Lynch Syndrome

Article Author:
Prianka Bhattacharya
Article Editor:
Terri McHugh
10/27/2018 12:31:42 PM
PubMed Link:
Lynch Syndrome


Colorectal cancer is the third most common cancer in men and women and the second leading cause of cancer-related deaths in the United States, with an estimated 134,490 new cases in 2016 and 49,190 deaths. Most colorectal cancers occur sporadically; however, inherited cancer syndromes or inherited mutations cause approximately 5% to 10% of cases. The most common hereditary form of hereditary colorectal cancer is Lynch syndrome, also known as Hereditary Non-Polyposis Colorectal Cancer Syndrome (HNPCC). Identifying patients with Lynch syndrome is clinically important because the marked increase lifetime risk of colorectal cancer ranges up to 80% and lifetime risk of endometrial cancer ranges up to 60%. Furthermore, there is an increased risk for other primary cancers including gastric, ovarian, small bowel, urothelial (ureter, renal pelvis), biliary tract, pancreatic, brain cancers (glioblastoma), sebaceous gland adenomas, and keratoacanthomas.


Lynch syndrome results from a germline mutation in one of four mismatch repair (MMR) genes called MLH1, MSH2, MSH6, and PMS2. Large deletions in a non-mismatch repair gene, called epithelial cellular adhesion molecule (EPCAM) which silences MSH2 expression, have also been found to cause Lynch syndrome. Mismatch repair genes are necessary for repairing incorrect pairing of nucleotide bases during DNA replication. If these “mismatches” are not corrected, then the resulting copy may not function properly leading to an increased risk for cancer. Individuals with Lynch syndrome are born with one functional allele (copy) of a specific gene and one non-functional allele of a specific gene due to an inherited mutation. The risk for cancer occurs when a mutation is acquired in the functional allele. Of note, on the rare occasion, an individual is not born with Lynch syndrome but develops a tumor with loss of both alleles leading somatic loss of the MMR proteins. Screening for Lynch syndrome can be performed on colorectal and endometrial tumor tissue by immunohistochemical staining (IHC) for the four mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) and/or microsatellite instability testing (MSI).

Lynch syndrome is inherited in an autosomal dominant manner. Thus first-degree relatives (parents, siblings, children) have a 50% chance to be affected with Lynch syndrome.


Lynch syndrome accounts for 2% to 4% of all colorectal cancer cases and approximately 2.5% of endometrial cancer cases. In fact, one out of 35 colorectal cancers and one out of 50 endometrial cancers is attributable to Lynch syndrome. The mean age at diagnosis of colorectal cancer in affected patients is 44 to 61 years, while for endometrial cancer mean age at diagnosis is 48 to 62 years.


Individuals with Lynch syndrome tend to have fewer than ten adenomatous polyps cumulatively in their life. Adenomas are commonly seen in patients younger than the age of 40 and frequently have a villous growth pattern with moderate to high-grade dysplasia. Adenomas in individuals with Lynch syndrome tend to transform to cancers more rapidly than in individuals in the general population with adenomas. Both adenomas and colon tumors associated with Lynch syndrome occur most frequently on the right side of the colon. Tumors are also noted to have a characteristic phenotype, including poor differentiated medullary-type carcinoma, mucinous adenocarcinoma, signet-ring cells, and a Crohn-like reaction with infiltrating lymphocytes.

History and Physical

Screening and subsequent germline mutation testing typically identify patients with Lynch syndrome. Those at risk for Lynch syndrome may be identified if they have a personal or family history of malignancy and meet clinical criteria, for example, the Amsterdam II or Revised Bethesda guidelines (Table 1), for screening. Further, patients with colorectal cancer who are found to have microsatellite instability in a tumor sample can be diagnosed with Lynch syndrome if they have a germline mutation in a mismatch repair gene. An individual with Lynch syndrome is at increased risk of colonic and extracolonic tumors, including endometrial, ovarian, upper gastrointestinal tract, urothelial, pancreatic, and brain cancers.


Current approaches to screening guidelines for Lynch syndrome are published by the National Comprehensive Cancer Network. The National Comprehensive Cancer Network recommends immunohistochemical staining of the mismatch repair proteins in all colorectal cancer tumors in all patients with colorectal cancer younger than age 70 and those older than age 70 meeting Bethesda criteria and endometrial tumors diagnosed in patients younger than the age of 50.

The two methods used to screen for Lynch syndrome are immunohistochemical staining and/or microsatellite instability testing. Concordance is high between these tests, and both have been found to be highly sensitive and specific; both have a false negative rate of about 5% to 10%.

Immunohistochemical staining is performed on a tumor sample to look for expression of proteins encoded by mismatch repair genes. If staining for expression of all mismatch repair proteins is present, a mismatch repair gene mutation is unlikely to be present. This is a normal result and referred to as mismatch repair-proficient. If staining is negative for expression of at least one mismatch repair protein, this is referred to as mismatch repair-deficient, and germline genetic testing should be offered. Of note, if immunohistochemical staining for MLH1 (either alone or with PMS2) is abnormal (not expressed) in colorectal tumor tissue, this should be followed by testing for BRAF V600E mutation or hypomethylation of the MLH1 promoter (in blood or normal tissue). If this testing is positive, it suggests a sporadic colorectal cancer rather than Lynch syndrome, and if negative germline mutation testing for Lynch syndrome should follow. For more information, please refer to National Comprehensive Cancer Network Screening Guidelines for Colorectal Cancer. 

Microsatellite instability is another screening test for Lynch syndrome and is characterized by variations in length of repetitive DNA sequences known as microsatellites in the human genome which occur as a result of the loss of mismatch repair activity. Identification of microsatellite instability technique involves testing for nucleotide markers. If a tumor is found to have a certain proportion of abnormal microsatellite repeat markers, it is considered to be microsatellite instability-high. mismatch repair-proficient is generally equivalent to microsatellite instability-low. The great majority of Lynch syndrome tumors are microsatellite instability-high; however, this pattern can be observed sporadic colorectal cancers thus germline testing is recommended for microsatellite instability-high tumors.

Among sporadic colorectal cancers, 10% to 15% exhibit deficiency of at least one mismatch repair protein and/or are microsatellite instability-high most often as a result of abnormal methylation of the MLH1 gene promoter and not due to Lynch syndrome. Therefore, screening with microsatellite instability and/or immunohistochemical staining alone is not adequate to diagnosed Lynch syndrome and must be followed by germline mutation testing. This is accomplished by DNA sequencing and large rearrangement analysis. Genetic testing should be preceded by genetic counseling due to the complexities of test selection. 

Patients identified to have abnormal immunohistochemical staining and/or abnormal microsatellite instability testing, but in whom germline testing does not reveal a mutation may be a result of a double somatic mismatch repair gene mutations in the tumor DNA or may still have undetected Lynch syndrome and management should be based on the personal/family history.

Clinical Testing Criteria (based on personal and family history)

Assessment for Lynch syndrome begins with taking a thorough family cancer history, which includes both maternal and paternal relatives and at least three generations made up of first, second, and third-degree relatives. All cancers should be noted, including the age of diagnosis, if available. Genetic testing for Lynch syndrome should be considered for patients who meet:

  • Amsterdan II criteria (Table 1A) 
  • Revised Bethesda guidelines (Table 1B)
  • Endometrial cancer diagnosed before age 50
  • Known Lynch syndrome in the family
  • Testing should also be considered in patients with at least 5% risk of Lynch syndrome on MMRpro, PREMM, or MMRpredict prediction models

Table 1. Amsterdam II Criteria and Revised Bethesda Guidelines

A. Amsterdam II Criteria 

  • More than three relatives with a Lynch syndrome-related cancer (colorectal, endometrial, small bowel, ureter or renal pelvis), with one being a first that meet the following criteria:
  • More than two successive generations affected
  • One is a first-degree relative of the other two
  • More than one relative is diagnosed younger than age 50
  • No evidence of Familial Adenomatous Polyposis (FAP)

B. Revised Bethesda Guidelines

  • Colorectal cancer diagnosed in a patient younger than age 50
  • Presence of synchronous or metachronous, colorectal, or other Lynch syndrome-related tumors*, regardless of age
  • Colorectal cancer with microsatellite instability-high histology (tumor infiltrating lymphocytes, Crohn like lymphocytic reaction, mucinous or signet-ring differentiation, or medullary growth pattern)
  • Colorectal cancer diagnosed in a patient with one or more first-degree relatives with a Lynch syndrome-related cancer*, with one of the cancers diagnosed before age 50
  • Colorectal cancer diagnosed in a patient with two or more first- or second-degree relatives with Lynch syndrome-related cancers* regardless of age

* Lynch syndrome-related cancers include colorectal, endometrial, gastric, ovarian, pancreas, ureter and renal pelvis, biliary tract, brain (usually glioblastoma as seen in Turcot syndrome), and small intestinal cancers, as well as sebaceous gland adenomas and keratoacanthoma (as seen in Muir-Torre syndrome).

Use of Amsterdan and Bethesda criteria to identify patients with Lynch syndrome misses approximately 50%, whereas about 50% of patients meeting criteria do not have Lynch syndrome.

Individuals identified by tumor testing with immunohistochemical staining and/or microsatellite instability or meeting testing criteria are recommended to consider Lynch syndrome-specific gene testing or multi-gene testing of affected family members is encouraged; however, when no affected member is available, testing of unaffected individuals should be considered.

Treatment / Management

Lynch Syndrome Management   

Individuals found to have a deleterious Lynch syndrome mutation are at increased cancer risk with the greatest risk of colorectal and endometrial cancers, followed by gastric and ovarian cancers. Fortunately, there are risk management guidelines for carriers of Lynch syndrome which are associated with a decrease in cancer-related deaths. Recommended surveillance for Lynch syndrome carriers is outlined as follows:

Screening/Risk Reduction Guidelines for MLH1, MSH2, MSH6, PMS2 and EPCAM mutation carriers


  • Colonoscopy beginning at age 20 to 25 repeating every one to two years; or two to five years before the earliest colorectal cancer if diagnosed before age 25 years.


  • Can be performed if colon cancer is diagnosed or if an advanced adenoma is found that cannot be otherwise removed. Because surgical management is evolving, the option of segmental or extended segmental colectomy for patients with confirmed adenocarcinoma and/or adenomatous polyps is based on individual considerations and discussion of risk. Follow-up surveillance with lower endoscopic examination is suggested every one to two years postoperatively.
  • Can be considered if surveillance measures cannot be followed.

Endometrium (Uterus) and Ovaries in females           

  • Pelvic exam, transvaginal ultrasound, endometrial aspiration and/or CA-125 can be considered on an individual basis. The efficacy of this regimen remains uncertain.          
  • Any abnormal uterine/vaginal bleeding warrants immediate evaluation.

Hysterectomy with Salpingo-Oophorectomy (Females)

  • Recommended when childbearing is complete

Other Extracolonic Cancers (**MLH1, MSH2 and EPCAM mutation carriers only)

** The risk for other Lynch syndrome-related malignancies is reported to be low in MSH6 and PMS2 carriers; due to limited data, the NCCN does not make recommendations for management for these other MSH6- and PMS2-related malignancies at this time. Recommendations can be made by treating physician(s).

  • Upper endoscopy (esophagogastroduodenoscopy) with extended duodenoscopy every three to five years beginning at age 30 to 35 years can be considered in select individuals or families or those of Asian descent. Consider testing and treating for H. Pylori.
  • Urinalysis, consider beginning annually between age 30 to 35. (The optimal age to begin screening for urinary tract cancers has not been determined, but the risk for developing such types of cancer before age 30 years is low).
  • No additional surveillance for central nervous system/brain and pancreatic tumors beyond annual physical/neurologic examination, starting at age 25 to 30 is recommended at this time.
  • Despite data indicating an increase in pancreatic cancer risk, no effective screening techniques have been identified; thus, no guidelines exist that this time.
  • Of note, it remains unclear whether there is an increased risk of breast cancer in individuals with Lynch Syndrome; therefore breast cancer screening is currently based on personal and family history.

Non-steroidal anti-inflammatory drugs (NSAIDs)

  • The efficacy of non-steroidal anti-inflammatory drugs in individuals with Lynch syndrome is under investigation. There is data suggesting aspirin use may decrease the risk of colon cancer in Lynch syndrome, but the optimal dose and duration remains uncertain.

A diagnosis of Lynch syndrome in a patient can also be of significance for at-risk family members. Patients should be advised to discuss with family members regarding possible cancer risk and their opportunity for testing, screening, and surveillance. At-risk family members should be offered genetic counseling, and testing if desired

Pearls and Other Issues

Lynch syndrome is the most common form of hereditary colorectal cancer, also known as hereditary nonpolyposis colorectal cancer syndrome. The mechanism underlying this disease involves inherited mutations in DNA mismatch repair genes, leading to inadequate expression and function of their proteins. Mutations in mismatch repair genes have been discovered and implicated in this disease, and clinical features have been identified and tailored to identify at-risk patients. As Lynch syndrome is inherited in an autosomal dominant manner, screening and identifying patients with Lynch syndrome and Lynch syndrome-associated cancers is imperative to decrease mortality and morbidity associated with this disease.

Lynch syndrome carriers are at increased risk of developing colorectal cancers and extracolonic cancers including endometrial, gastric, ovarian, pancreas, ureter and renal pelvis, biliary tract, brain (usually glioblastoma as seen in Turcot syndrome), small intestinal cancers, and sebaceous gland adenomas, and keratoacanthoma (as seen in Muir-Torre syndrome). Screening for colorectal cancers has shown proven beneficial in detecting colorectal cancers and reducing mortality, while the value of screening for extracolonic cancers remains unclear. Ongoing research may better delineate risk and guidelines for screening, surveillance, and treatment of Lynch syndrome carriers.


Hereditary Colorectal Cancer Syndromes., Wells K,Wise PE,, The Surgical clinics of North America, 2017 Jun     [PubMed PMID: 28501250]
Identifying Lynch Syndrome in Women Presenting With Endometrial Carcinoma Under the Age of 50 Years., Anagnostopoulos A,McKay Mrcpch VH,Cooper I,Campbell F,Greenhalgh L,Kirwan J,, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017 May 12     [PubMed PMID: 28498244]
Universal molecular screening does not effectively detect Lynch syndrome in clinical practice., Brennan B,Hemmings CT,Clark I,Yip D,Fadia M,Taupin DR,, Therapeutic advances in gastroenterology, 2017 Apr     [PubMed PMID: 28491141]
Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications., Lynch HT,Boland CR,Gong G,Shaw TG,Lynch PM,Fodde R,Lynch JF,de la Chapelle A,, European journal of human genetics : EJHG, 2006 Apr     [PubMed PMID: 16479259]
Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer., Hampel H,, Journal of the National Comprehensive Cancer Network : JNCCN, 2010 May     [PubMed PMID: 20495086]
Microsatellite instability in cancer of the proximal colon., Thibodeau SN,Bren G,Schaid D,, Science (New York, N.Y.), 1993 May 7     [PubMed PMID: 8484122]
Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1., Ligtenberg MJ,Kuiper RP,Chan TL,Goossens M,Hebeda KM,Voorendt M,Lee TY,Bodmer D,Hoenselaar E,Hendriks-Cornelissen SJ,Tsui WY,Kong CK,Brunner HG,van Kessel AG,Yuen ST,van Krieken JH,Leung SY,Hoogerbrugge N,, Nature genetics, 2009 Jan     [PubMed PMID: 19098912]
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study., Kempers MJ,Kuiper RP,Ockeloen CW,Chappuis PO,Hutter P,Rahner N,Schackert HK,Steinke V,Holinski-Feder E,Morak M,Kloor M,Büttner R,Verwiel ET,van Krieken JH,Nagtegaal ID,Goossens M,van der Post RS,Niessen RC,Sijmons RH,Kluijt I,Hogervorst FB,Leter EM,Gille JJ,Aalfs CM,Redeker EJ,Hes FJ,Tops CM,van Nesselrooij BP,van Gijn ME,Gómez García EB,Eccles DM,Bunyan DJ,Syngal S,Stoffel EM,Culver JO,Palomares MR,Graham T,Velsher L,Papp J,Oláh E,Chan TL,Leung SY,van Kessel AG,Kiemeney LA,Hoogerbrugge N,Ligtenberg MJ,, The Lancet. Oncology, 2011 Jan     [PubMed PMID: 21145788]
Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology., Provenzale D,Gupta S,Ahnen DJ,Bray T,Cannon JA,Cooper G,David DS,Early DS,Erwin D,Ford JM,Giardiello FM,Grady W,Halverson AL,Hamilton SR,Hampel H,Ismail MK,Klapman JB,Larson DW,Lazenby AJ,Lynch PM,Mayer RJ,Ness RM,Regenbogen SE,Samadder NJ,Shike M,Steinbach G,Weinberg D,Dwyer M,Darlow S,, Journal of the National Comprehensive Cancer Network : JNCCN, 2016 Aug     [PubMed PMID: 27496117]
Genetic counseling and cascade genetic testing in Lynch syndrome., Hampel H,, Familial cancer, 2016 Jul     [PubMed PMID: 26969309]
Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study., Goodfellow PJ,Billingsley CC,Lankes HA,Ali S,Cohn DE,Broaddus RJ,Ramirez N,Pritchard CC,Hampel H,Chassen AS,Simmons LV,Schmidt AP,Gao F,Brinton LA,Backes F,Landrum LM,Geller MA,DiSilvestro PA,Pearl ML,Lele SB,Powell MA,Zaino RJ,Mutch D,, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015 Dec 20     [PubMed PMID: 26552419]
Hereditary colorectal cancer syndromes: American Society of Clinical Oncology clinical practice guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology clinical practice guidelines., Stoffel EM,Mangu PB,Limburg PJ,, Journal of oncology practice, 2015 May     [PubMed PMID: 25829526]
Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer)., Hampel H,Frankel WL,Martin E,Arnold M,Khanduja K,Kuebler P,Nakagawa H,Sotamaa K,Prior TW,Westman J,Panescu J,Fix D,Lockman J,Comeras I,de la Chapelle A,, The New England journal of medicine, 2005 May 5     [PubMed PMID: 15872200]
Identification of Lynch syndrome among patients with colorectal cancer., Moreira L,Balaguer F,Lindor N,de la Chapelle A,Hampel H,Aaltonen LA,Hopper JL,Le Marchand L,Gallinger S,Newcomb PA,Haile R,Thibodeau SN,Gunawardena S,Jenkins MA,Buchanan DD,Potter JD,Baron JA,Ahnen DJ,Moreno V,Andreu M,Ponz de Leon M,Rustgi AK,Castells A,, JAMA, 2012 Oct 17     [PubMed PMID: 23073952]
EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome., Palomaki GE,McClain MR,Melillo S,Hampel HL,Thibodeau SN,, Genetics in medicine : official journal of the American College of Medical Genetics, 2009 Jan     [PubMed PMID: 19125127]
Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians., Hendriks YM,de Jong AE,Morreau H,Tops CM,Vasen HF,Wijnen JT,Breuning MH,Bröcker-Vriends AH,, CA: a cancer journal for clinicians, 2006 Jul-Aug     [PubMed PMID: 16870997]
A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer., Boland CR,Thibodeau SN,Hamilton SR,Sidransky D,Eshleman JR,Burt RW,Meltzer SJ,Rodriguez-Bigas MA,Fodde R,Ranzani GN,Srivastava S,, Cancer research, 1998 Nov 15     [PubMed PMID: 9823339]
Clues to the pathogenesis of familial colorectal cancer., Aaltonen LA,Peltomäki P,Leach FS,Sistonen P,Pylkkänen L,Mecklin JP,Järvinen H,Powell SM,Jen J,Hamilton SR,, Science (New York, N.Y.), 1993 May 7     [PubMed PMID: 8484121]
Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients., Aaltonen LA,Peltomäki P,Mecklin JP,Järvinen H,Jass JR,Green JS,Lynch HT,Watson P,Tallqvist G,Juhola M,, Cancer research, 1994 Apr 1     [PubMed PMID: 8137274]
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts., Vasen HF,Blanco I,Aktan-Collan K,Gopie JP,Alonso A,Aretz S,Bernstein I,Bertario L,Burn J,Capella G,Colas C,Engel C,Frayling IM,Genuardi M,Heinimann K,Hes FJ,Hodgson SV,Karagiannis JA,Lalloo F,Lindblom A,Mecklin JP,Møller P,Myrhoj T,Nagengast FM,Parc Y,Ponz de Leon M,Renkonen-Sinisalo L,Sampson JR,Stormorken A,Sijmons RH,Tejpar S,Thomas HJ,Rahner N,Wijnen JT,Järvinen HJ,Möslein G,, Gut, 2013 Jun     [PubMed PMID: 23408351]
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC., Vasen HF,Watson P,Mecklin JP,Lynch HT,, Gastroenterology, 1999 Jun     [PubMed PMID: 10348829]
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability., Umar A,Boland CR,Terdiman JP,Syngal S,de la Chapelle A,Rüschoff J,Fishel R,Lindor NM,Burgart LJ,Hamelin R,Hamilton SR,Hiatt RA,Jass J,Lindblom A,Lynch HT,Peltomaki P,Ramsey SD,Rodriguez-Bigas MA,Vasen HF,Hawk ET,Barrett JC,Freedman AN,Srivastava S,, Journal of the National Cancer Institute, 2004 Feb 18     [PubMed PMID: 14970275]
Clinical diagnosis and management of hereditary colorectal cancer syndromes., Vasen HF,, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000 Nov 1     [PubMed PMID: 11060333]
Lynch syndrome: genetics, natural history, genetic counseling, and prevention., Lynch HT,Lynch J,, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000 Nov 1     [PubMed PMID: 11060321]
Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer., Barnetson RA,Tenesa A,Farrington SM,Nicholl ID,Cetnarskyj R,Porteous ME,Campbell H,Dunlop MG,, The New England journal of medicine, 2006 Jun 29     [PubMed PMID: 16807412]
Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer., Järvinen HJ,Mecklin JP,Sistonen P,, Gastroenterology, 1995 May     [PubMed PMID: 7729632]
Hereditary colorectal cancer., Lynch HT,de la Chapelle A,, The New England journal of medicine, 2003 Mar 6     [PubMed PMID: 12621137]
Identifying Lynch syndrome., de la Chapelle A,Palomaki G,Hampel H,, International journal of cancer, 2009 Sep 15     [PubMed PMID: 19536819]
Identification of mismatch repair genes and their role in the development of cancer., Fishel R,Kolodner RD,, Current opinion in genetics & development, 1995 Jun     [PubMed PMID: 7549435]
Lynch Syndrome, Kohlmann W,Gruber SB,,, 1993     [PubMed PMID: 20301390]